Materials:
Capillary tubes
1.5 mL Eppendorf microfuge tubes
15 mL conical centrifuge tubes
96-well V-bottom plates (Corning Costar 3894, from Fisher)
Flow tubes (Falcon 352054)
Reagents:
0.5 M EDTA pH 8.0
PBS + 0.5% heat inactivated FBS
RBC Lysis Buffer
4.15 g NH4Cl
0.5 g NaHCO3
0.0186 g Disodium EDTA
200 mL H2O
| Antibodies: | [Final] | Catalog # |
| Fc Block (2.4G2) | 1:1000 | Pharmingen 553142 |
| FITC-IgG2b Isotype | 1:100 | Pharmingen 553988 |
| PE-IgG2a Isotype | 1:100 | Pharmingen 553930 |
| Mac-1 (CD11b)-IgG2b-FITC | 1:100 | Pharmingen 553310 |
| Gr-1(Ly6G)-IgG2b-FITC | 1:100 | Pharmingen 553127 |
| CD3-IgG2b-FITC | 1:100 | Pharmingen 555274 |
| LY5a (CD45.2)-Biotin (recognizes C57) | 1:100 | Pharmingen 553771 |
| Ly5b (CD45.1)-PE (recognizes SJL) | 1:100 | Pharmingen 553776 |
| Streptavidin-TriColor (SATC) | 1:100 | Caltag SA1006 |
Procedure:
Collect 200 - 500 uL blood from each mouse. Mix with 50 uL 0.5M EDTA in 1.5 mL eppendorf tubes.
Add 250 uL blood to 5 mL RBC Lysis Buffer (20x vol. blood) in 15 mL conical tubes.
Spin down white cells 1500 RPM x2 min.
Aspirate lysate and wash by resuspending cells in 5 mL PBS/FBS.
Spin down at 1500 RPM x2 min.
Resuspending cells in 500 uL PBS/FBS with 1 uL Fc Block (1/500)
Add 150 uL to each well of a 96 well V-bottom dish.
Add 50 uL 1o Ab Master Mix (the mix is a 1/25 dilution of each 1o Ab in PBS/FBS).
Include 1 well with a combination of Isotype controls for setting voltage. Also include 1 well for each of the 1o Ab as single positive controls for setting compensation.
Incubate 60 min at 4oC.
Spin 1500 RPM x2 min. Discard supernatant by shaking it out once into the sink, and blot inverted plate on paper towel.
Wash by adding 200 uL PBS/FBS to each well, and mix by pipetting up and down.
Immediately spin at 1500 RPM x2 min. and discard supernatant.
Add 150 uL of 2o Ab (i.e. Streptavidin-TC) Master Mix.
Incubate 30 min at 4oC, then spin at 1500 RPM x5 min. Shake out supernatant.
Resuspend in 200 - 500 uL of PBS/FBS and transfer to 5 mL flow tubes.
See the flow cytometry protocol for 3-color flow.
蛋白質作為構成人體組織器官的支架和主要物質,在人體生命活動中起著重要作用。蛋白質的相互作用能產生許多效應,如形成特異底物作用通道、生成新的結合位點、失活、作用底物專一性和動力學變化等,細胞的代謝、信號......
2021年9月9日,無錫臻和生物科技有限公司(以下簡稱“臻和科技”)與美國VyantBio公司簽署TissueofOrigin?(以下簡稱“TOO?”)全球權益和ZL轉讓協議,全資收購這款唯一獲FDA......
2021年7月20日,JournalofCellularPhysiology及JournalofCellularBiochemistry同時撤回了中國學者49篇文章。從2019年開始,Journalo......
研究闡明了SETD2在調控骨髓增生異常綜合征(MDS)向急性髓系白血病(AML)轉化過程中的作用機制,為MDS臨床治療提供了理論基礎和潛在靶標。MDS是最常見的髓系惡性腫瘤之一,是起源于造血干細胞的一......
為什么有些癌癥治療之后仍會復發?有時候,癌癥的相關治療可以有效地將癌細胞消除到無法檢測的水平,但是,如果停止治療,癌癥可能會復發。例如,在用酪氨酸激酶抑制劑藥物治療慢性粒細胞白血病患者是就會出現停藥后......
化療已使最常見的兒童期癌癥---急性淋巴細胞白血病(ALL)---成為最可治愈的癌癥之一,但是科學家們有證據表明這種治療也可能使某些患者復發。在一項新的研究中,來自中國和美國的研究人員報道由治療引起的......
磷酸甘油酸突變酶1(PGAM1)通過其代謝活性以及與其他蛋白質(例如α平滑肌肌動蛋白(ACTA2))的相互作用,在癌癥代謝和腫瘤進展中起關鍵作用。變構調節被認為是發現針對PGAM1的高選擇性和有效抑制......
2018年12月6日,來自圣迭戈的消息——Illumina公司(納斯達克股票代碼:ILMN)今天宣布推出新型高密度基因分型芯片Infinium?GlobalDiversityArray。這款芯片設計源......
在一項新的研究中,來自美國俄亥俄州大學的DaniloPerrotti和同事證實一種叫做FTY720的藥物能夠抑制由癌癥蛋白BCR-ABL導致的白血病小鼠模型的病情。由于這種藥物還能夠誘導從白血病患者獲......
來自中山大學有害生物控制與資源利用國家重點實驗室(StateKeyLaboratoryofBiocontrol,原生物防治國家重點實驗室),基因工程教育部重點實驗室(KeyLaboratoryofGe......